Details of the Drug Reposition

General Information of This Drug (ID: DMV52CP)

Drug Name
BUCINDOLOL   DMV52CP
Synonyms
Bucindolol; 71119-11-4; Bucindolol [INN:BAN]; Bucindololum [INN-Latin]; CHEMBL321582; C22H25N3O2; NCGC00167817-01; 2-(2-Hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)benzonitrile; DSSTox_RID_81872; DSSTox_CID_26744; DSSTox_GSID_46744; Bucindololum; 2-[2-Hydroxy-3-[2-(indol-3-yl)-1,1-dimethylethylamino]propoxy]benzonitrile; Benzonitrile, 2-(2-hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-; 2-[2-Hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]benzonitrile
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Atrial fibrillation DIS15W6U BC81.3 Phase 2/3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hypertension DISLL965 BA00-BA04 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01970501) Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure. U.S. National Institutes of Health.